SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Kiley Alison (Last) (First) (Middle) ONE EMBARCADERO CENTER SUITE 3700 (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Aegerion Pharmaceuticals, Inc. [ AEGR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/27/2010
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2010		C		1,186,064	A	(1)	1,186,064	I	See Footnotes(2)(3)
Common Stock	10/27/2010		C		414,388	A	(4)	1,600,452	I	See Footnotes(3)(5)
Common Stock	10/27/2010		C		764,310	A	$7.6	2,364,762	I	See Footnotes(3)(6)
Common Stock	10/27/2010		P		315,789	A	$9.5	2,860,551	I	See Footnotes(3)(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	10/27/2010		C			3,064,681	(8)	(8)	Common Stock	1,186,064	$0	0	I	See Footnotes(2)(3)
Series B Convertible Preferred Stock	(4)	10/27/2010		C			679,018	(9)	(9)	Common Stock	414,388	$0	0	I	See Footnotes(3)(5)
Senior Subordinated Convertible Promissory Notes	$7.6	10/21/2010		A		$5,808,837.78		(10)	12/31/2011	Common Stock	764,310	$0	$5,808,837.78	I	See Footnoes(3)(11)
Senior Subordinated Convertible Promissory Notes	$7.6	10/27/2010		C			$5,808,837.78	(10)	12/31/2011	Common Stock	764,310	$0	$0	I	See Footnotes(3)(6)

Explanation of Responses:

1. Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series A Share converted into 0.38701117412 shares of common stock.

2. Alta BioPharma Partners III, L.P. ("ABPIII") acquired 1,086,336 shares of common stock upon the conversion of its Series A Shares, Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG") acquired 72,957 shares of common stock upon the conversion of its Series A Shares, and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") acquired 26,771 shares of common stock upon the conversion of its Series A Shares.

3. The Reporting Person is a member of Alta BioPharma Management III, LLC ("ABMIII"), which is the general partner of ABPIII and the managing limited partner of ABPIIIKG. She may be deemed to share investment power over the securities of the Issuer held by ABPIII, ABPIIIKG and AEBPIII with the directors of ABMIII and managers of AEBPIII but disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.

4. Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, automatically converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. Each Series B Share converted into 0.61027657931 basis of common stock.

5. ABPIII acquired 379,545 shares of common stock upon the conversion of its Series B Shares, ABPIIIKG acquired 25,490 shares of common stock upon the conversion of its Series B Shares, and AEBPIII acquired 9,353 shares of common stock upon the conversion of its Series B Shares.

6. ABPIII acquired 700,050 shares of common stock upon the conversion of its Convertible Notes, ABPIIIKG acquired 47,010 shares of common stock upon the conversion of its Convertible Notes, and AEBPIII acquired 17,250 shares of common stock upon the conversion of its Convertible Notes.

7. ABPIII acquired 289,236 shares of common stock in the Issuer's public offering, ABPIIIKG acquired 19,425 shares of common stock in the Issuer's public offering, and AEBPIII acquired 7,128 shares of common stock in the Issuer's public offering. All shares were purchased at the initial public offering price of $9.50 per share.

8. The Series A Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.

9. The Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.

10. The Convertible Notes were issued on September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010 and October 1, 2010. Any outstanding principal amount and accrued but unpaid interest thereon was automatically convertible into shares of capital stock of the Issuer upon the consummation of specified sale transactions involving the securities of the Issuer, including an initial public offering of the Issuer's common stock meeting certain conditions.

11. ABPIII acquired Convertible Notes with a face amount, including principal and accrued interest, of $5,320,408.54; ABPIIIKG acquired Convertible Notes with a face amount, including principal and accrued interest, of $357,311.91; and AEBPIII acquired Convertible Notes with a face amount, including principal and accrued interest, of $131,117.33.

	/s/ Christine A. Pellizzari, attorney-in-fact	10/27/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.